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Abstract
Both orexin and neurotensin are expressed in the lateral hypothalamic area (LHA) and have been implicated in the
regulation of feeding, motor activity and the reward system. A double label immunofluorescence and in situ hybridization
studies showed that neurotensin colocalizes with orexin in neurons of the LHA. Pharmacological studies suggested that
neurotensin excites orexin-producing neurons (orexin neurons) through activation of neurotensin receptor-2 (NTSR-2) and
non-selective cation channels. In situ hybridization study showed that most orexin neurons express neurotensin receptor-2
mRNA but not neurotensin receptor-1 (Ntsr-1) mRNA. Immunohistochemical studies showed that neurotensin-
immunoreactive fibers make appositions to orexin neurons. A neurotensin receptor antagonist decreased Fos expression
in orexin neurons and wakefulness time in wild type mice when administered intraperitoneally. However, the antagonist did
not evoke any effect on these parameters in orexin neuron-ablated mice. These observations suggest the importance of
neurotensin in maintaining activity of orexin neurons. The evidence presented here expands our understanding of the
regulatory mechanism of orexin neurons.
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Introduction
Neurotensin is a 13 amino-acid residue neuropeptide implicated
in neuroendocrine function, feeding behavior and the reward
system. Neurotensin acts on three subtypes of neurotensin
receptors (NTSRs); NTSR-1, NTSR-2, and NTSR-3. NTSR-1
and NTSR-2 are G-protein coupled receptors, while NTSR-3 is
a single transmembrane receptor [1,2]. NTSR-1 couples to Gq
proteins and activates phospholipase C (PLC) and inositol
phosphate (IP) signaling [3,4]. NTSR-2 shows lower affinity to
neurotensin, and its physiological role remains unclear. Little is
known about the physiological role of NTSR-3 [5].
Orexin A and orexin B (also known as hypocretin 1 and
hypocretin 2) are neuropeptides that are expressed in a population
of neurons in the lateral hypothalamic area (LHA) [6,7].
Disruption of this neuropeptide system causes narcolepsy in
human and animals, suggesting that orexins are crucial regulators
of sleep and wakefulness [8]. Orexin-producing neurons (orexin
neurons) send axonal projections widely in CNS regions that
regulate emotion, sleep, wakefulness, arousal, the reward system
and energy homeostasis [9]. Especially dense projections of orexin
neurons are found in the monoaminergic and cholinergic nuclei in
the hypothalamus and brainstem [10–15]. Orexin neurons
regulate cholinergic/monoaminergic neurons to maintain a long,
consolidated waking period. Orexin neurons receive abundant
input from the limbic system, preoptic area, posterior hypothal-
amus and brain stem [16,17].
Activity of orexin neurons is regulated by a number of factors,
including cholecystokinin, neurotensin, vasopressin, oxytocin,
neuropeptide Y (NPY), adenosine, serotonin, and noradrenaline
[18–22]. In addition, orexin neurons contain other peptides
including dynorphin, and neuronal activity-regulated pentraxin
(Narp) [23–25]. These factors may play cooperative roles with
orexin, although orexin is likely to play a central role in the
function of these neurons, because orexin2/2 mice and orexin
neuron-ablated mice show almost the same phenotype [26].
Both neurotensin and orexin have been shown to localize in the
LHA and activate dopaminergic neurons in the ventral tegmental
area (VTA). A recent study showed that mice null for the leptin
receptor (LepRb) specifically in neurotensin neurons showed early-
onset obesity, modestly increased feeding, and decreased locomo-
tor activity. This study also showed that neurotensin neurons send
innervations to orexin neurons [27].
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Here, we further studied the interaction of neurotensin and
orexin and investigated the physiological relevance of this
interaction in vivo. We found that many neurotensin-expressing
neurons in the LHA also produce orexins. We also show that
neurontensin plays an important role in maintenance of activity of
orexin neurons and physiological regulation of sleep/wakefulness
states.
Results
Neurotensin and orexin are co-localized in the lateral
hypothalamic area
Immunostaining showed that many neurotensin-containing cells
were observed in the LHA, zona incerta (ZI) and central nucleus of
the amygdala (CeA) (Figure 1A). Orexins are also well known to be
expressed in the LHA [10,15,28]. Although neurotensin-positive
neurons were distributed more widely in the brain (Figure 1A, also
see Allen Brain Atlas, Nts-Coronal-05-3215: Nts_260 (position:
6500)), with several discrete regions containing many positive cells,
including the LHA, ZI, and CeA, the regions of distribution of
orexin neurons and neurotensin neurons in the LHA partially
overlapped.
We first examined the relationship between these neuropeptides
in the LHA by dual-labeling immunofluorescent study (Figure 1B,
upper panels). This study revealed that 82% of orexin neurons in
the LHA also expressed neurotensin. We also observed the
existence of neurotensin-positive neurons in the arcuate nucleus
(ARC) in the same section. However, we did not find any co-
localization of orexin in these cells, although we observed orexin-ir
fibers in this region (Figure 1B, lower panels). This observation
confirmed the specific labeling of orexin and neurotensin.
Double label in situ hybridization also confirmed the co-
localization (Figure 1C D). This study showed that 84% of orexin
neurons also expressed Neurotensin mRNA, being concordant with
the result of double immunofluorescence. Likewise, 27% of
neurotensin neurons in the LHA expressed Orexin mRNA.
By in situ hybridization, we also found that the number of
Neurotensin-positive neurons in the LHA of orexin/ataxin-3 mice, in
which orexin neurons are specifically ablated [26], was markedly
lower than that in wild- type mice with the same genetic
background (C57BL/6J) (Figure 1D). This finding further supports
that some neurotensin-containing neurons in the LHA are orexin
neurons, which are specifically ablated in orexin/ataxin-3 mice [26].
Neurotensin activates orexin neurons
Recent studies have suggested that the activity of orexin neurons
is influenced by various factors [8]. We previously found that
neurotensin increases the intracellular calcium concentration
([Ca2+]i) of orexin neurons [19]. We analyzed the mechanisms
by which neurotensin activates orexin neurons in detail by patch
clamp electrophysiological studies using brain slice preparations
from orexin/EGFP mice [29]. Under whole-cell current clamp
mode, neurotensin (100 nM) bath application depolarized orexin
neurons, with an increase in firing frequency (Figure 2A).
Neurotensin (100 nM) significantly increased the firing frequency
to 663 6 243% (n= 6, p= 0.0123) of control. Depolarization was
also observed in the presence of TTX (Figure 2A) (6.060.7 mV,
n= 5), suggesting that neurotensin directly activates orexin
neurons. The response peaked 40–80 sec after application of
neurotensin, and the membrane potential returned to the basal
level in 2–4 min after washout. The majority of GFP-positive
neurons tested were depolarized by neurotensin (91%, 64 out of
70), and a few orexin neurons showed no response or slight
depolarization (9%, 6 out of 70). On the other hand, 56% (10 out
of 18) of GFP-negative neurons in the same area were depolarized
by neurotensin and the rest showed no response to neurotensin.
Figure 2B demonstrates that neurotensin depolarized orexin
neurons in the presence of TTX in a concentration-dependent
manner; EC50 and maximum effect (Emax) were 3.8460.02 nM
and 7.6060.01 mV, respectively (n = 3–5). At a holding potential
of 260 mV under voltage clamp, neurotensin (10 nM) induced an
inward current in orexin neurons in the presence of TTX
(6.461.7 pA; n= 5) (Figure 2F).
Neurotensin receptor-2 (NTSR-2) is involved in
neurotensin-induced excitation of orexin neurons
To identify the subtypes of neurotensin receptors involved in
neurotensin-induced excitation of orexin neurons, we used a non-
selective neurotensin receptor antagonist, SR142948, and an
NTSR-2 selective antagonist, levocabastine. Under voltage-clamp
mode in calcium-free extracellular solution, at a holding potential
of 240 mV, neurotensin (10 nM) induced 25.763.5 pA of inward
current (n = 7) (Figure 2C). The neurotensin-induced inward
current in orexin neurons was significantly and almost completely
inhibited by SR142948 or levocabastine (Figure 2C). In the
presence of 10 mM SR142948 or 1 mM levocabastine, the
neurotensin-induced current was inhibited to 1.060.7 pA (n= 7,
p,0.0001) or 2.761.2 pA (n= 7, p,0.0001), respectively
(Figure 2C, right panel).
To histologically examine the expression of Ntsr-1 and Ntsr-2 in
orexin neurons, we performed double in situ hybridization, using
DIG-labeled antisense riboprobes for Ntsr-1 or Ntsr-2 mRNA
together with FITC-labeled antisense riboprobes for prepro-orexin
mRNA. This study revealed that Ntsr-2-expressing cells, presum-
ably including astrocytes, exist diffusely in the CNS, consistent
with previous observations [30,31]. Orexin mRNA was colocalized
with Ntsr-2 mRNA in the LHA (Figure 2D). On the other hand,
Ntsr-1 was not detected in the LHA, although abundant expression
of Ntsr-1 was observed in the VTA (not shown). These results
suggest that NTSR-2, a levocabastine-sensitive subtype of
neurotensin receptor, is almost exclusively involved in neuroten-
sin-induced activation of orexin neurons.
Activation of non-selective cation channels is involved in
neurotensin-induced activation of orexin neurons
To examine the mechanisms of the neurotensin-induced current
in more detail, additional electrophysiological experiments were
performed. First, the effect of extracellular Na+ in neurotensin-
induced depolarization was studied. Experiments were performed
in which NaCl in the extracellular solution was replaced by an
equimolar concentration of choline chloride in the presence of
TTX (1 mM). When choline was substituted for sodium, neuro-
tensin-induced depolarization was strongly depressed. In Na+-free
solution, neurotensin (10 nM)-induced depolarization was de-
creased from 6.060.8 mV (n= 4) to 2.160.8 mV (n= 4)
(Figure 2E) (p = 0.0114), suggesting that neurotensin-induced
depolarization is primarily dependent on extracellular Na+. Next,
to examine the contribution of calcium ions in this response,
calcium was removed from the extracellular solution. Removal of
extracellular calcium markedly potentiated the neurotensin-
induced inward current measured by voltage clamp recording
holding at 260 mV (Figure 2F). In the presence and absence of
calcium ions in the extracellular solution, the neurotensin (10 nM)-
induced inward current was 6.461.7 pA (n= 5) and 25.763.5 pA
(n= 7), respectively (p = 0.0015). Therefore, the neurotensin-
induced inward current increased about 4 fold in calcium-free
solution, suggesting that it was physiologically suppressed by
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Figure 1. Neurotensin colocalizes with orexin in LHA neurons. A, Immunostaining of neurotensin in a coronal section of mouse brain. Dense
staining of neurotensin-like immunoreactivity is observed in the central nucleus of the amygdala (CeA), lateral hypothalamic area (LHA) and zona
incerta (ZI). B, Double immunofluorescence study showing that neurotensin-containing neurons also express orexin in the LHA but not in the arcuate
nucleus (ARC). Upper panels, neurotensin (green)- and orexin (red)-like immunoreactivity in the LHA (upper panels) and arcuate nucleus (lower
pannels). Scale bar indicates 20 mm. C, Double-label in situ hybridization histochemistry showing distribution of orexin (brown) and neurotensin (blue)
mRNAs. Left panel, Representative low power image of the LHA region (bregma21.46 mm) of a coronal section of C57BL/6 mouse brain. Right panel,
higher power view of the region indicated by a black rectangle in the left panel. Yellow arrowheads show prepro-orexin mRNA, and blue arrowheads
show neurotensin mRNA. Red arrowheads show neurons expressing both neurotensin and orexin mRNAs. Rectangles show typical examples of orexin-
single-positive, neurotensin-single-positive, and double-positive cells. Scale bar indicates 20 mm. D, Numbers of neurotensin- or orexin-positive
neurons in LHA of wild-type (Wild-Type, n = 5) and orexin-ataxin-3 (Ataxin-3, n = 5) mice revealed by double labeling in situ hybridization. White, grey
and black bars show neurotensin-, orexin- and double-positive neurons, respectively.
doi:10.1371/journal.pone.0062391.g001
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extracellular calcium ions. The reversal potential of the neuroten-
sin-induced current in potassium-free and calcium-free extracel-
lular solution (in mM: 140 NaCl, 2 CsCl, 1 MgCl2, 1 EGTA, 10
HEPES, 10 glucose) was near 0 mV (26.4 mV, n= 6–10) when
measured using a CsCl pipette solution (in mM: 145 CsCl, 1
MgCl2, 10 HEPES, 1.1 EGTA, 0.5 Na2GTP, and 2 MgATP)
(Figure 2G). This reversal potential is consistent with activation of
nonselective cation channels. Several recent reports suggest that
the transient receptor potential (TRP) channel family plays an
important role in the receptor-operated influx of cations [32,33].
In addition, the current through TRP channels is known to be
suppressed by the presence of extracellular calcium ions, as with
neurotensin-induced inward currents (Figure 2F)[34,35]. Collec-
tively, our observations suggest that TRP channels are involved in
neurotensin-induced activation of orexin neurons. To evaluate this
possibility, the effect of SKF96365, which is often used as a TRP
channel blocker [36], was tested on neurotensin-induced depolar-
ization of orexin neurons. SKF96365 significantly inhibited
neurotensin-induced depolarization (Figure 2H). In the presence
and absence of SKF96365 (10 mM), neurotensin-induced depo-
larization was 0.2560.25 mV (n= 4) and 6.0060.71 mV (n= 5),
respectively (Figure 2H) (p = 0.0002). This observation further
supports the idea that neurotensin activates orexin neurons
through TRP channels.
Effects of neurotensin antagonists on activity of orexin
neurons in vivo
We found that neurotensin-immunoreactive fibers make appo-
sitions to orexin neurons by immunohistochemical studies
(Figure 3A). To decipher the physiological relevance of neuroten-
sin in maintaining the activity of orexin neurons in vivo, we
intraperitoneally administered a non-selective specific neurotensin
antagonist SR142948 in male mice at 8:45 and examined the
activity of orexin neurons by means of Fos immunostaining at
9:45. We found that SR142948 (1 mg/kg) administration signif-
icantly decreased the number of orexin neurons expressing Fos
immunoreactivity (Control, 46.6065.42% (n= 6);SR142948,
29.2562.31% (n= 6), p = 0.0146) (Figure 3B, C). In contrast, the
number of MCH neurons expressing Fos immunoreactivity in the
same area was not affected by SR142948 (Control, 8.0361.23%
(n= 6), SR142948, 7.8461.14% (n= 6), p = 0.9113) (Figure 3C).
The decrease of Fos expression in orexin neurons was also
observed when SR142948 was administered at 20:45 and
examined at 21:45 (Control, 79.0062.21% (n= 5); SR142948,
49.8061.51% (n= 5), p,0.0001) (Figure 3C). We obtained similar
result when SR142948 was administered the third ventricle at
10:00 (Figure S1). These observations support the idea that
neurotensin maintains the activity of orexin neurons but not MCH
neurons in vivo.
We also examined the effect of SR142948 on behavioral level.
We examined the effect of SR142948 on sleep/wakefulness states
in mice. SR142948 (1 mg/kg or 3 mg/kg), dissolved in dimethyl
sulfoxide (DMSO) and diluted in saline to a final concentration of
1% DMSO, was administered intraperitoneally to mice at the start
of the light phase (08:45) or dark phase (20:45). Control injection
was performed with saline containing the same concentration of
DMSO as with injection of SR142948. EEG and EMG were
recorded for four hours to score sleep/wakefulness states.
Wild-type mice injected with SR142948 showed a significantly
shorter wakefulness time and longer NREM and REM sleep times
as compared with mice with vehicle injection for 2 hour after
administration at the start of the light period (Figure 4A, lower
panels). This effect was dose-dependent, and accompanied by
lengthening of both NREM and REM sleep time (Figure 4A,
lower panels). Fast Fourier transform (FFT) revealed that the
microarchitecture of the EEG spectra during the non-REM phase
of saline- and SR-injected groups two hours after injection were
identical in both wildtype and orexin-ataxin 3 mice, suggesting the
antagonist induced normal NREM sleep (r = 0.999281 and
0.99577 for saline vs SR 1 mg and 3 mg, respectively in wild
type mice, r = 0.987997 and 0.999455 for saline vs SR 1 mg and
3 mg, respectively in orexin-ataxin 3 mice) (Figure S3).
To examine whether this effect of SR142948 is caused by
inhibition of orexin neuronal activity, we also administered
SR142948 to orexin/ataxin-3 mice in which orexin neurons are
genetically ablated [26]. SR142948 failed to influence any sleep
parameters in the orexin/ataxin-3 transgenic mice (Figure 4B, D).
We did not find any effects of SR142948 on sleep parameters in
both wild-type and orexin/ataxin-3 mice in the dark period. This
result is consistent with a recent report showing that optogenetic
inhibition of orexin neurons induces NREM sleep in the light
period, but not in the dark period [37]. Orexin in CSF are known
to show circadian variation, high at the end of active period[38].
In order to examine the possibility that abundant orexin in the
extracellular space eliminated the effect of neurotensin blocker, we
also performed the experiment at the end of dark period
(SR142948 was administered 2hr before the end of dark period).
We again failed to find effect of SR142948 on sleep parameters in
wild type or orexin/ataxin-3 mice (Figure S2). This observation
further suggested a possibility that the blockade of neurotensin
does not evoke the effect on the activity of orexin neurons during
the level of endogenous orexin is high [39].
These observations suggest that neurotensin physiologically
maintains activity of orexin neurons, and inhibition of the
neurotensinergic system affects the activity of orexin neurons to
increase NREM sleep in the light period.
Discussion
Neurotensin is involved in autoactivation of orexin
neurons
LHA neurons express a variety of neuropeptides, including
orexin, melanin-concentrating hormone, QRFP and neurotensin
[9,27,40,41]. Among them, both neurotensin and orexin have
been implicated in feeding and reward systems, and shown to
activate dopaminergic neurons in the VTA [42]. Functional
interaction between these peptides might have an important
physiological role.
The present study showed that orexin neurons in the LHA co-
expressed neurotensin (Figure 1B, C). The finding that the number
of neurotensin neurons in the LHA was decreased in orexin/ataxin-
3 mice further suggests the co-localization of neurotensin and
orexin (Figure 1D). In addition, neurotensin activated most of the
orexin neurons (64 of 70). Orexin neurons are reported to be
innervated by orexin-immunoreactive fibers and activated by
orexins through orexin 2 receptors [39]. Recently, it was shown
that neurotensin-immunoreactive fibers also make appositions to
orexin neurons [27]. We also found that neurotensin-immunore-
active fibers made appositions to orexin neurons (Figure 3A).
These findings suggest a possibility that neurotensin released from
orexin neurons also acts as an auto-stimulator of orexin neurons.
Some of these neurotensin-immunoreactive fibers are likely to
come from neurotensin-containing neurons in the LHA, which
also express orexin, suggesting that neurotensin is involved in
autoregulation of orexin neuronal activity. Neurotensinergic
neurons in the preoptic area, bed nucleus of the stria terminals,
central nucleus of the amygdala, and the VTA are other possible
sources for these innervations, because these regions were reported
A Role of Neurotensin in Orexin Neurons
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to contain neurotensinergic neurons [43] and to innervate orexin
neurons [16,17].
These findings suggest that neurotensin is colocalized in some
orexin neurons and is involved in auto-regulation of these neurons
through autocrine and/or paracrine mechanisms. We found that
neurotensin-positive neurons in the LHA of orexin neuron-
ablated, orexin/ataxin-3 mice were markedly decreased as
compared with wild type mice (Figure 1D). A recent study showed
that mice null for the leptin receptor (LepRb) specifically in
neurotensin neurons showed early-onset obesity, modestly in-
creased feeding, and decreased locomotor activity [27]. These
observations raise a possibility that the late onset obesity seen in
orexin-ataxin 3 mice might partly stem from the decreased basal
neurotensin level in these mice.
Neurotensin activates orexin neurons through NTSR-2
and non-selective cation channels
Neurotensin-induced depolarization and the inward current
were not affected by TTX, suggesting a direct postsynaptic effect.
Studies using selective antagonists suggested that NTSR-2 is
involved in neurotensin-induced activation of orexin neurons,
because a NTSR-2 antagonist, levocabastine, almost completely
abolished the response. Additionally, in situ hybridization histo-
chemistry revealed that most of the orexin neurons expressed Ntsr-
2 mRNA (Figure 2D). We also found that neurotensin activated
non-selective cation channels in orexin neurons (Figure 2E-H),
which are similar to the channels activated by CCK-8S [19],
vasopressin and oxytocin [22]. The inward current induced by
neurotensin was strongly potentiated by the removal of extracel-
lular calcium ions and was inhibited by SKF96365. These
characteristics are similar to those of nonselective cation channels
activated by CCK-8S, vasopressin and oxytocin in orexin neurons,
suggesting that the same non-selective cation channels might be
involved in the neurotensin-induced response. TRP-C channels
are a possible candidate for such channels because they have been
shown to be activated by diacyl glycerol produced by the
phospholipase C pathway [44], which is downstream of Gq-
coupled receptors such as Ntsr-2. The current through TRP
channels is known to be increased by the removal of extracellular
calcium ions[34,35], further supporting the possibility of the
involvement of this type of channel in the response.
Physiological relevance of neurotensin-mediated
activation of orexin neurons
We hypothesized that the basal activity of orexin neurons might
be at least partially maintained by neurotensin. To evaluate this
possibility, we administered a non-selective neurotensin receptor
antagonist, SR142948, to mice, and examined the number of
orexin neurons that showed Fos-like immunoreactivity in their
nuclei. SR142948 significantly decreased the number of Fos-
positive orexin neurons in both dark and light periods (Figure 3B,
C). Next, to examine the behavioral effects induced by the
decrease in activity of orexin neurons by SR142948, we examined
the effect of SR142948 on sleep/wakefulness states in mice. We
observed that SR142948 decreased wakefulness time accompanied
by increased NREM and REM sleep times in wild-type mice for
two hours when administered at the start of the light period
(Figure 4). However, it failed to elicit any effect on sleep/
wakefulness parameters in orexin/ataxin-3 transgenic mice
(Figure 4B, D). Although wakefulness time in orexin/ataxin-3 mice
was comparable to that in wild-type mice, which is consistent with
our previous data [26], SR142948 did not elicit effects on sleep/
wakefulness states in orexin/ataxin-3 mice, suggesting that effects of
neurotensin on the activity of orexin neurons play an important
role in sleep/wake regulation (Figure 4). These observations
suggest that neurotensin affects sleep/wakefulness states through
regulating the activity of orexin neurons.
We observed a longer wakefulness time after injection of saline
at the start of the light period as compared with SR142948
injection or orexin/ataxin-3 mice with both saline and SR142948
injection. This might suggest that stress induced by the injection
procedure increased wakefulness time in wild-type mice with saline
injection through excitation of orexin neurons, and this effect was
blocked by SR142948.
We did not find any obvious effect of SR142948 on sleep/
wakefulness behavior in wild-type mice when administered at the
start of the dark period. This is consistent with a report that
showed that acute optogenetic silencing of orexin neurons
decreased wakefulness time during the light period, but not during
the dark period [37]. This might suggest that because the firing
rate of orexin neurons is high in the dark period, and released
orexin peptide has a long half-life in the extracellular space, acute
silencing of orexin neurons failed to affect behavioral state.
Administration of SR142948 two hours before the end of dark
period, when CSF orexin level is high, also failed to evoke any
effect on sleep parameters in wild type mice (Figure S2), further
supporting this idea. However, during the light period, since the
firing rate of orexin neurons is relatively low, and only a small
amount of orexin peptide is released, inhibition of orexin neurons
might efficiently affect the behavioral state. Alternatively, the
arousal-regulated region might be already sufficiently activated
without the help of the orexin system during the dark period;
Figure 2. Neurotensin activates orexin neurons. A, Whole cell current clamp recording of orexin neurons shows that neurotensin (100 nM)
depolarized orexin neurons in the absence (top) or presence (bottom) of TTX (1 mM). B, Concentration dependence of neurotensin-induced
depolarization (mV) in the presence of TTX. EC50 and Emax were 3.8460.02 nM and 7.6060.01 mV, respectively (n = 3–5). C, Effects of NTSR-1 or
NTSR-2 antagonist on effects of neurotensin on orexin neurons. Both SR142948 (n = 7, 10 mM), a non-selective antagonist, and levocabastine (n = 7,
1 mM), an NTSR-2 preferential antagonist, almost completely blocked the effects of neurotensin-induced inward current in orexin neurons. Left panel,
a typical trace. Right panel, effect of neurotensin-induced current in orexin neurons in the presence of SR142948 or lebocavastine. Extracellular
solution was used as vehicle control. D, Double-labeling in situ hybridization shows most neurons expressing orexin mRNA (red) also express Ntsr-2
mRNA (blue). Black arrowheads show colocalization. Scale bar indicates 20 mm. E, Effect of extracellular Na+ on neurotensin-induced depolarization.
NaCl was replaced by an equimolar concentration of choline chloride in the presence of TTX (1 mM) (Na+-free). Neurotensin (10 nM)-induced
depolarization was markedly decreased in Na+-free solution (n = 4). F, Effect of extracellular Ca2+ on neurotensin-induced inward current. Neurotensin
(10 nM) induced an inward current in the presence of extracellular calcium. This inward current was markedly increased in Ca2+-free extracellular
solution (n = 7). Lower panel shows the fold-increase in inward current (pA) in Ca2+-free solution. G, Current-voltage relationship obtained by the
current step protocol using a CsCl pipette in K+- and Ca2+-free extracellular solution. The steady state potential, at the end of the current step (marked
by circle in left panel), is plotted in the current-voltage relationship in the right panel. I-V curve shows that the reversal potential of the neurotensin
(10 nM)-induced current was 9.82 mV (n= 6–10). Neurons were current-clamped and the current was stepped from –240 pA to +280 pA (with
increments of 40 pA with a duration of 100 ms). Open circle indicates control and filled circle indicates neurotensin (10 nM) application. H, Effects of
non-selective cation channel blocker, SKF96365. Left panel, SKF96365 (10 mM) inhibited neurotensin-induced depolarization. Right panel, Bar graph
indicates that SKF96365 inhibited neurotensin-induced depolarization (n = 4). Values are mean6S.E.M. *, p,0.05.
doi:10.1371/journal.pone.0062391.g002
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therefore, silencing of orexin neurons might fail to affect the
behavior of mice.
Our present study suggested that neurotensin colocalizes with
orexin and plays an important role in maintaining the activity of
orexin neurons. Recently, it was shown that orexin neurons are
activated by orexin itself [39]. These two mechanisms might co-
operatively and redundantly maintain the firing rate of orexin
neurons.
Ntsr-2-expressing cells, including astrocytes, exist diffusely in the
CNS [2,45]. Therefore, to examine the precise role of neuroten-
sin-mediated regulation of orexin neurons, mice with spatially-
restricted disruption of Neurotensin or Ntsr-2 in orexin neurons
would be required. Such a genetic model would further reveal the
physiological relevance of the neurotensin-orexin system, including
its role in the regulation of dopaminergic neurons.
In conclusion, neurotensin colocalizes with orexin and activates
orexin neurons. This activation involves NTSR-2-mediated
activation of TRP channels. These influences of neurotensin on
orexin neurons are necessary to maintain the activity of orexin
neurons in vivo, and might have an important role in the
autoregulatory function of the orexin system.
Figure 3. Neurotensinergic fibers appose orexin neurons. A, Double immunofluorescence study shows that many varicose terminals with
neurotensin-like immunoreactivity (green) make appositions to orexin neurons (red) in the LHA (Left panels). Right panel, high power view of
rectangular region in left panel. B, Photomicrograph showing distribution of Fos (black nuclear label) and orexin (brown label) expression in LHA.
Scale bar indicates 40 mm. Upper panels, left panel, control (saline injection); right panel, SR142948 injection at 20:45. Animals were sacrificed at 21:45
and subjected to immunostaining. Lower panels, left panel, control (saline injection); right panel, SR142948 injection at 8:45. Animals were sacrificed
at 9:45 and subjected to immunostaining. C, SR142948 administration decreased Fos immunoreactivity of orexin neurons, but not in MCH neurons.
doi:10.1371/journal.pone.0062391.g003
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Experimental Procedures
Drugs
Neurotensin (Peptide Institute, Osaka, Japan), SKF96365
(Sigma, St. Louis, MO), CNQX, AP-5 (Wako, Osaka, Japan),
picrotoxin, tetrodotoxin (TTX) (Wako), SR142948 (TOCRIS
Bioscience, Bristol, UK), pyrilamine (Sigma) and levocabastine
(Sigma) were dissolved in extracellular solution.
Animals
All experimental procedures involving animals were approved by
the Animal Experiment and Use Committee of Kanazawa
University (AP-101567) and were in accordance with NIH
guidelines. All efforts were made to minimize animal suffering
and discomfort and to reduce the number of animals used.
Genetically-modified mice used in this study were orexin/EGFP
mice [46] and orexin/ataxin-3 mice [26]. These mice were crossed to
wild type C57BL/6J mice for more than seven generations. Wild-
type littermates of these transgenic mice were used as the wild-type
controls. Mice were maintained under a strict 12 hour light:dark
cycle (light on at 8:45 a.m., off at 8:45 p.m.) in a temperature (22uC)
and humidity controlled room and fed ad libitum.
In situ hybridization
Double in situ hybridization was performed according to
procedures previously described [47]. Digoxigenin (DIG)-labeled
riboprobes for Neurotensin were synthesized from a 510 bp frag-
ment of murine Neurotensin cDNA (nucleotides 296 2 +605 from
the initiation codon) containing 510 bp of the whole coding region
cloned into pCRII vector (Invitrogen). Fluorescein (FITC)-labeled
riboprobes for prepro-orexin were synthesized by in vitro transcrip-
tion with pBluescript II SK (+) containing a 0.5 kb fragment
encoding Gln33-Val130 of rat prepro-orexin [7]. Digoxigenin (DIG)-
labeled riboprobes for mNtsr-1 were synthesized from a 0.86 kb
fragment of mNtsr-1 cDNA (nucleotides 2233 2 +627 from the
initiation codon) containing 0.23 kb of the 59-noncoding region
and the 59-most 0.63 kb of the coding region cloned into
pBluescript IISK (+). Full-length cDNA for mNtsr-2 cloned in
pBluescript II SK (-) was donated by Dr. Wada. Digoxigenin
(DIG)-labeled riboprobes for mNtsr-2 were synthesized by in vitro
transcription using this construct. The DIG and FITC-labeled
probes were detected by anti-DIG (1/2000) and anti-FITC (1/
1000) antibodies conjugated with alkaline phosphatase (Roche
Diagnostics, Basel, Switzerland). Alkaline phosphatase activity was
detected with NBT/BCIP and INT/BCIP (Roche Diagnostics).
Immunohistochemistry
Mice were anesthetized deeply with diethyl ether and perfused
sequentially with 20 ml ice-cold saline and 20 ml cold 4%
paraformaldehyde in 0.1 M phosphate buffer. The brains were
removed and immersed in the same fixative solution for 24 hr at
4uC, and then immersed in 30% sucrose solution for at least 2
days. The brains were quickly frozen in embedding solution
(Sakura Finetechnical Co. Ltd., Tokyo, Japan) and cut into
coronal sections using a cryostat (HM 505E, Microm, Walldorf,
Germany). To detect orexin and neurotensin immunoreactivity,
coronal brain sections of C57BL/6 mice were incubated with goat
anti-orexin antibody (1:1000, Santa Cruz Biotechnology, Inc.
Figure 4. A neurotensin receptor antagonist SR142948 dose-dependently decreased wakefulness time and duration during the
lights on period in wild-type mice, but not in orexin neuron-ablated mice. Hourly amounts (A, B) and average episode duration (C, D) of
awake, non-REM, and REM sleep states (mean6SE) plotted over 4 hr after administration of saline (dotted line) or SR142948 (solid line) in wild-type
(n = 27, 14 and 7 for saline, SR 1 mg/kg, and 3 mg/kg, respectively) (A, C) and orexin/ataxin-3 mice (n = 14, 14 and 7 for saline, SR 1 mg/kg, and 3 mg/
kg, respectively) (B, D). Data for the dark phase are displayed in shaded panels. SR142948 was administered at the start of light or dark periods (8:45
or 20:45).
doi:10.1371/journal.pone.0062391.g004
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Santa Cruz, CA, USA) at 4uC overnight, followed by incubation
with Alexa Fluor 546-conjugated donkey anti-goat IgG (1:400,
Invitrogen Corp., Carlsbad, CA, USA) for 1.5 h at RT. Next, the
same sections were incubated with rabbit anti-neurotensin
antibody (1:10,000, Merck KGaA, Darmstadt, Germany) at 4uC
overnight. After washing with PBS, the sections were incubated
with Alexa Fluor 488-labeled goat anti-rabbit IgG (1:400,
Invitrogen Corp.) for 1.5 h at RT. Double immunolabeling was
detected with the aid of a fluorescence microscope (Zeiss Z1, Carl
Zeiss AG, Go¨ttingen, Germany) fitted with an optical-sectioning
system (Zeiss Apotome, Carl Zeiss AG). To detect Fos immuno-
reactivity in orexin-expressing neurons, the sections were incubat-
ed with guinea pig anti-orexin antibody (Molecular Probes,
1:1000; brown color) and rabbit anti-cFos antibody Ab-5
(Calbiochem, 1:20000; black color).
Quantitative analysis of immunolabeling
Cell counting was performed to determine numbers of orexin
neurons, neurotensin neurons and Fos-expressing neurons. All
orexin-positive, MCH-positive and neurotensin-positive neurons
were counted bilaterally in the LHA, regardless of the intensity of
their staining. For Fos counting, cells were considered Fos positive
if their nucleus contained detectable black immunolabeling,
regardless of the labeling intensity, and Fos negative if they
displayed no visible nucleus or a nucleus lacking Fos immunola-
beling. To obtain accurate estimates of cell number in sections, we
used the three-dimensional counting method as described [48].
Electrophysiological recording
Orexin/EGFP mice (2–6 weeks old) were anesthetized with
isoflurane (Abbott, Osaka, Japan). The mice were decapitated
under deep anesthesia. Brains were isolated in ice-cold cutting
solution consisting of (mM): 280 sucrose, 2 KCl, 10 HEPES, 0.5
CaCl2, 10 MgCl2, 10 glucose, pH 7.4, bubbled with 100% O2.
Brains were cut coronally into 300-mm slices with a vibratome
(VTA-1000S, Leica, Germany). Slices containing the LHA were
transferred for 1 hr to an incubation chamber at room
temperature filled with physiological solution containing (mM):
140 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose,
pH 7.4 with NaOH. These slices were transferred to a recording
chamber (RC-27L, Warner Instrument Corp., CT, USA) at RT
on a fluorescence microscope stage (BX51WI, Olympus, Tokyo,
Japan). The fluorescence microscope was equipped with an
infrared camera (C-3077 78, Hamamatsu Photonics, Hamamatsu,
Japan) for infrared differential interference contrast (IR-DIC)
imaging and a CCD camera (JK-TU53H, Olympus) for fluores-
cent imaging. Neurons that showed GFP fluorescence were
subjected to patch-clamp recordings. Recordings were carried
out with an Axopatch 200B amplifier (Axon Instruments, Foster
City, CA) using a borosilicate pipette (GC150-10, Harvard
Apparatus, Holliston, MA) prepared using a micropipette puller
(P-97, Sutter Instruments, Pangbourne, UK) and filled with
intracellular solution (4–10 MV) consisting of (mM): 125 K-
gluconate, 5 KCl, 1 MgCl2, 10 HEPES, 1.1 EGTA-Na3, 5
MgATP, 0.5 Na2GTP, pH 7.3 with KOH. Osmolarity of the
solution was checked with a vapor pressure osmometer (model
5520, Wescor, Logan, UT). The osmolarity of the internal and
external solutions was 280–290 and 320–330 mOsm/l, respec-
tively. The liquid junction potential of the patch pipette and
perfused extracellular solution was estimated to be 216.2 mV and
was applied to the data. The recording pipette was under positive
pressure while it was advanced toward individual cells in the slice.
Tight seals of 0.5–1.0 GV were made by negative pressure. The
membrane patch was then ruptured by suction. The series
resistance during recording was 10–25 MV and was compensated.
The reference electrode was an Ag-AgCl pellet immersed in bath
solution. During recordings, cells were superfused with extracel-
lular solution at a rate of 1.0–2.0 ml/min using a peristaltic pump
(Minipuls3, Gilson, Paris, France) at RT. Depolarizing and
hyperpolarizing current pulses were applied to cells for durations
of 200 msec at 20 pA steps at 2-sec intervals from the resting
membrane potential (260 mV) set by varying the intensity of
a constantly injected current.
Intracerebroventricular administration
Male mice (8 to 10 weeks old) were anesthetized with sodium
pentobarbital (0.5 mg/kg, i.p.), positioned in a stereotaxic frame
(David Kopf Instruments), and a guide cannula was implanted in
the lateral ventricle under sterile conditions. The coordinates used
to map the correct positioning of the implants were 0.2 mm
posterior to the bregma, 0 mm lateral to the midline, and 5 mm
below the skull surface. Mice were then housed singly for a recovery
period of at least 7 days. SR142948 was dissolved in physiological
saline, and delivered at a volume of 3 ml over 60 sec, and the injector
was left in position for a further 60 sec to ensure complete dispersal.
Administration was performed during the light period (10:00AM).
Sleep recordings
An electrode for EEG and EMG recording was implanted in the
skull of each mouse. The three arms of the electrode for EEG
recording were placed approximately 2 mm anterior and 2 mm to
the right, 2 mm posterior and 2 mm to the right, and 2 mm
posterior and 2 mm to the left of the bregma. Stainless steel wires
for EMG recording were sutured to the neck muscles of each
mouse bilaterally, and each electrode was glued solidly to the skull.
After the recovery period, animals were moved to a recording cage
placed in an electrically shielded and sound attenuated room. A
cable for signal output was connected to the implanted electrode
and animals were allowed to move freely. Signals were amplified
through an amplifier (AB-611J, Nihon Koden, Tokyo) and
digitally recorded on a computer using EEG/EMG recording
software (Vital recorder, Kissei Comtec). Animals were allowed at
least seven days to adapt to the recording conditions prior to any
EEG/EMG recording session. Following the adaptation period,
each animal was intraperitoneally administered both SR142948
and saline on separate experimental days with a 3-day interval.
The order of injection (i.e. either SR142948 first or saline first) was
randomized. EEG/EMG data were evaluated and staged for
4 hours after administration. Data acquired on the day of saline
administration were used as control. We analyzed FFT spectra of
NREM period in 1-2hr epoch of saline- or SR-injected mice
(N= 17). Power spectral analysis of EEG signals was performed
using custom FFT software.
Statistical analysis
Data were analyzed by two-way ANOVA followed by post hoc
analysis of significance by Fisher’s protected least significant
difference test using the Stat View 5.0 software package for
Macintosh (Abacus Concepts, Berkeley, CA, USA). Probability (p)
values less than 0.05 were considered statistically significant.
Supporting Information
Figure S1 Effect of icv administration of SR142948 on Fos
expression in orexin neurons. A, Photomicrograph showing
distribution of Fos (black nuclear label) and orexin (brown label)
expression in LHA. Scale bar indicates 40 mm. Left panel, control
(saline injection); right panel, SR142948 (5.0 nmol) injection at
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10:00. Animals were sacrificed at 13:00 and subjected to
immunostaining. B, SR142948 administration decreased Fos
immunoreactivity of orexin neurons in a concentration-dependent
manner (Control, 37.2763.95%, n= 6; SR142948 (0.5 nmol),
31.2865.11%, n= 6, p= 0.3762; SR142948 (5.0 nmol),
23.1062.22%, n= 6, p = 0.0108, Student’s t test) (left panel), but
MCH neurons showed no response to SR 142948 (right panel).
(TIF)
Figure S2 Effect of a neurotensin receptor antagonist SR142948
on sleep parameters in wild-type mice and orexin/ataxin-3 mice
when administered at two hours before the end of dark period.
Hourly amounts (A, B) and average episode duration (C, D) of
awake, non-REM, and REM sleep states (mean6SE) plotted over
4 hr after administration of saline (dotted line) or SR142948 (solid
line) in wild-type (n = 14) (A, C) and orexin/ataxin-3 mice (n = 14)
(B, D). Data for the dark phase are displayed in shaded panels.
(TIF)
Figure S3 Fast Fourier transform (FFT) revealed that the
microarchitecture of the EEG spectra during the non-REM phase
of saline- and SR-injected groups two hours after injection at the
start of light phase are identical.
(TIF)
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